Cytoki Pharma

Executive Summary

Cytoki Pharma is a clinical-stage biotechnology company pioneering long-acting interleukin-22 (IL-22) analogues for metabolic diseases and epithelial injury. Based in Copenhagen, Denmark, the company is developing CK-0045, its lead asset, which is currently in Phase 2 clinical trials for type 2 diabetes and obesity. IL-22 is a cytokine that promotes tissue regeneration and metabolic homeostasis, offering a novel mechanism with potential to address both glycemic control and weight loss. Additionally, Cytoki is exploring CK-0045 for inflammatory bowel disease (IBD), leveraging IL-22's role in intestinal barrier repair. Cytoki Pharma is positioned in a competitive landscape but differentiates itself with a first-in-class approach. The Phase 2 data readout for CK-0045 in metabolic indications is a key upcoming catalyst, with potential to validate the platform and attract partnerships. The company is private, and its valuation remains undisclosed. With a strong scientific foundation and a focus on high-need areas, Cytoki Pharma presents an attractive risk-reward profile for investors seeking early-stage exposure to novel biologics. The conviction score reflects the Phase 2 stage and the transformative potential of the IL-22 platform, tempered by clinical development risks.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 topline results for CK-0045 in type 2 diabetes40% success
• Q3 2026Initiation of Phase 2 trial for CK-0045 in inflammatory bowel disease60% success
• H2 2026Partnership or licensing deal for IL-22 platform30% success